AIM: To investigate the clinical effect of Ranibizumab combined with laser for diabetic macular edema and the effect on visual acuity.

METHODS: Totally 80 patients(138 eyes)with diabetic edema who were treated in our hospital from January 2015 to December 2015 were selected, and 40 patients were randomly divided into the combined group(67 eyes in 40 patients, treated by ranibizumab and laser therapy), the control group(71 eyes in 40 cases, laser treatment only). We compared the treatment effect of the two groups and the impact on the patient's vision.

RESULTS: After treated for 1wk, 3mo, and 6mo, the BCVA(LogMAR)and central macular thickness(CMT)values of the patients in the two groups were significantly lower than those before treatment(P<0.05); the BCVA(LogMAR)and CMT values of the combined group were lower than those of the control group, the difference was statistically significant(P<0.05). After treated for 1wk, 3mo, and 6mo, IOP of the two groups was not significantly different compared with before treatment(P>0.05); IOP value of combined group compared with those of the control group, was not significantly different(P>0.05).

CONCLUSION: The combination of ranibizumab and laser treatment for diabetic macular edema can more significantly reduce macular edema, improve visual acuity.